Pattern of disease-modifying therapies use and related adverse events among multiple sclerosis patients

Roney Pereira  Pinto; Charleston Ribeiro  Pinto; Sandro Rodrigues  Batista; Fernanda Costa  Nunes; Denise Sisterolli  Diniz

doi:10.1590/

Authors

Roney Pereira Pinto Programa de Pós-graduação em Ciências da Saúde, Faculdade de Medicina, Universidade Federal de Goiás Faculdade de Medicina, Goiânia, Brasil https://orcid.org/0000-0003-2442-9023
Charleston Ribeiro Pinto Curso de Farmácia, Departamento de Ciências e Tecnologias, Universidade Estadual do Sudoeste da Bahia, Jequié, Brasil; Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Brasil https://orcid.org/0000-0001-9999-054X
Sandro Rodrigues Batista Centro Estadual de Medicação de Alto Custo Juarez Barbosa, Secretaria de Estado da Saúde de Goiás, Goiânia, Brasil https://orcid.org/0000-0001-7356-522X
Fernanda Costa Nunes Departamento de Saúde Coletiva do Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás Faculdade de Medicina, Goiânia, Brasil https://orcid.org/0000-0001-5036-648X
Denise Sisterolli Diniz Programa de Pós-graduação em Ciências da Saúde, Faculdade de Medicina, Universidade Federal de Goiás Faculdade de Medicina, Goiânia, Brasil https://orcid.org/0000-0002-3078-6804

DOI:

https://doi.org/10.1590/

Keywords:

Adverse Events, Disease Modifying Therapies, Multiple Sclerosis, Treatment

Abstract

This study attempted to describe the disease modifying therapies (DMTs) use patterns and related adverse events in multiple sclerosis (MS) patients assisted by the Brazilian Unified Health System (SUS). This is a cross-sectional study conducted at a reference center in the Midwestern Brazil. Demographic, socioeconomic, and clinical data, and adverse events associated with DMTs were collected. We observed 291 patients with a mean age of 41.4 years, and mostly (68.6%) women. Most patients (58.8%) were using first-line treatment. Fingolimod (29.9%) and beta interferons (23.7%) were the most used drugs. About 74.2% of patients used DMTs for more than six months. In 26.5% of patients, 238 adverse events were reported, 67.2% of which were mild and 32.8% of which were moderate. The most frequent adverse events were headaches (6.9%), myalgia (3.8%), and flu-like symptoms (3.1%). The proportion of adverse events proportion ranged from 17.3% (natalizumab) to 41.2% (dimethyl fumarate). Most MS patients treated by SUS used first-line DMTs. After adjustment, there was noticed that adverse events associated with DTMs are twice as likely to occur in users of the first-line treatment than other lines (OR 1.99, p=0.01). It is essential to develop DMTs safety monitoring strategies to promote their rational use.

Downloads

Download data is not yet available.

References

Bianco J, Damasceno A, Becker J, Casarin F, Carlos N, Martins T, et al. Prevalência da esclerose múltipla em pacientes tratados com medicamentos modificadores do curso da doença utilizando dados do Sistema Único de Saúde brasileiro. J Bras Econ Saúde. 2023; 15(1): 12-23.

Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs. 2021; 35(8): 861-880.

Bose D, Ravi R, Maurya M, Pushparajan L, Konwar M. Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis. Mult Scler Relat Disord. 2022; 61.

Bossart J, Kamm C, Kaufmann M, Stanikić M, Puhan M, Kesselring J, et al. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry. Mult Scler Relat Disord. 2022; 60: 103706.

Brasil. Ministério da Saúde. Secretaria de Atenção Especializada à Saúde. Portaria Portaria no375. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla [Internet]. Brasilia: Ministério da Saúde; 2009. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/sas/2009/prt0375_10_11_2009.html

» https://bvsms.saude.gov.br/bvs/saudelegis/sas/2009/prt0375_10_11_2009.html

Brasil. Ministério da Saúde. Secretaria de Atenção Especializada à Saúde. Portaria Portaria no375. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla [Internet]. Brasília: Ministério da Saúde; 2019. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/Saes/2019/poc0007_11_07_2019.html

» https://bvsms.saude.gov.br/bvs/saudelegis/Saes/2019/poc0007_11_07_2019.html

Brasil. Ministério da Saúde. Secretaria de Atenção Especializada à Saúde. Portaria Conjunta no1, de 07 de janeiro de 2022. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla. [Internet]. Brasília: Ministério da Saúde; 2022. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/saes/2022/poc0001_31_01_2022.html

» https://bvsms.saude.gov.br/bvs/saudelegis/saes/2022/poc0001_31_01_2022.html

Bruce J, Jarmolowicz D, Lynch S, Thelen J, Lim S-L, Smith J, et al. How patients with multiple sclerosis weigh treatment risks and benefits. Health Psychol. 2018; 37(7): 680-690.

da Silva N, Takemoto M, Damasceno A, Fragoso Y, Finkelsztejn A, Becker J, et al. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. BMC Health Serv Res. 2016; 16: 102.

Ferraro D, Camera V, Baldi E, Vacchiano V, Curti E, Guareschi A, et al. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real- life multicenter study on persistence. Curr Med Res Opin. 2018; 34(10): 1803-1807.

Filippini G, Munari L, Incorvaia B, Ebers G, Polman C, D’Amico R, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003; 361(9357): 545–552.

Fragoso Y, Alves-Leon S, Arruda W, Carvalho M de J, Comini-Frota E, Corrêa É, et al. Natalizumab adverse events are rare in patients with multiple sclerosis. Arq Neuropsiquiatr. 2013; 71(3): 137-141.

Hartung DM, Johnston KA, McGregor JC, Bourdette DN. Characteristics of prescription drug use among individuals with multiple sclerosis in the us medicare population. Int J MS Care. 2022; 24(2): 90-97.

Jalkh G, Abi Nahed R, Macaron G, Rensel M. Safety of newer disease modifying therapies in multiple sclerosis. Vaccines (Basel). 2020; 9(2): 12.

Khatri BO. Fingolimod in the treatment of relapsing- remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord. 2016; 9(2): 130-147.

Kobelt G, Teich V, Cavalcanti M, Canzonieri A. Burden and cost of multiple sclerosis in Brazil. PLoS One. 2019; 14(1): e0208837.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov; 33(11).

Lawton MP, Brody EM. Assessment of older people: self- maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3): 179-86.

Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Autoimmun Ver. 2021; 20(6).

Lyrio A, Mega T, Lopes A, Ferré F, Barreira A, Portugal C, et al. OP152 Use of Real-world Evidence By The Brazilian Health Technology Assessment Committee (Conitec) For Monitoring Of Health Technologies. Int J Tech Assess Health Car. 2023; 39(S1): S45-S45.

Mantia L, Prone V. Headache in multiple sclerosis and autoimmune disorders. Neurol Sci. 2015; 36(Suppl 1): S75– S78.

Marques V, Passos G, Mendes M, Callegaro D, Lana- Peixoto M, Comini-Frota E, et al. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq Neuropsiquiatr. 2018; 76(8): 539-554.

Mathis A, Owens G. Implications for multiple sclerosis in the era of the Affordable Care Act: the shifting managed care landscape. Am J Manag Care. 2014; 20(11 Suppl): S242-53.

McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: A review. JAMA. 2021; 325(8): 765-779.

Polman H, O’Connor P, Havrdova E, Hutchinson M, Kappos L, Miller D, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9): 899-910.

Qian Z, Li Y, Guan Z, Guo P, Zheng K, Du Y, et al. Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019. Front Public Health. 2023; 17(11): 1073278.

Rafiee A, Ghadimi K, Ataei A, Askari M, Sheikhinia N, Tavoosi N, et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int J Physiol Pathophysiol Pharmacol. 2019; 11(4): 105-114.

Reen GK, Silber E, Langdon DW. Multiple sclerosis patients’ understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review. J Neurol Sci. 2017; 15(375): 107-122.

Ribeiro T, Duarte A, Silva D, Borges F, Costa V, Papais- Alvarenga R, et al. Prevalence of multiple sclerosis in Goiania, Goias, Brazil. Arq Neuropsiquiatr. 2019; 77(5): 352-356.

Simbrich A, Thibaut J, Khil L, Berger K, Riedel O, Schmedt N. Drug-use patterns and severe adverse events with disease- modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data. Neuropsychiatr Dis Treat. 2019; 28(15): 1439-1457.

Souza K, Diniz I, Lemos L, Junior N, Zuppo I, Teodoro J, et al. Effectiveness of first-line treatment for relapsing- remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. PLoS ONE. 2020; 15(9): e0238476.

Tilbery CP, Fazzito MM, Jordy SS, Thomaz RB, Fernandes IR. Efeitos adversos no tratamento da Esclerose Múltipla com drogas imunomoduladoras: experiência em 118 casos. Rev Neurocienc. 2009; 17(3): 220-225.

Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta- analysis. Cochrane Database Syst Rev. 2015; 2015(9).

Villani V, Prosperini L, De Giglio L, Pozzilli C, Salvetti M, Sette G. The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis. Headache. 2012; 52(7): 1130-5.

Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007; 63(2): 187-195.

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26(14): 1816-1821.

Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022; 269(4): 1861-1872.

World Health Organization. WHO. Division of Patient Safety. Department of Quality in Healthcare (‎ 2010)‎. Conceptual framework for the international classification for patient safety version 1.1: final technical report January 2009. Geneva: World Health Organization; 2010. 145 p.

Pattern of disease-modifying therapies use and related adverse events among multiple sclerosis patients

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

How to Cite